He took $200 from his father, a pharmaceuticals distributor, to initiate his business venture. Dilip Shanghvi, the founder and CEO of Sun Pharma, is a renowned figure in the health industry. He is an Indian billionaire entrepreneur and one of the nation’s wealthiest individuals. At 67 years old, he ranks as the second-richest pharma billionaire, trailing only Cyrus Poonawalla. In 1983, he established Sun Pharmaceutical Industries with the aim of producing psychiatric drugs. To set up his business, Dilip borrowed $200 from his father, who was a pharmaceuticals distributor.
According to Forbes, as of July 19, 2023, Dilip’s net worth stands at $17.8 billion (approximately Rs 1,46,090 crore). He holds the 97th position on the list of the world’s richest individuals, as per the magazine’s report on July 19. Back in 2016, he was the second richest person in India.
Dilip serves as the founder and CEO of Sun Pharmaceutical Industries, which currently boasts a market capitalization of 2.6 trillion INR (Rs 2,60,000 crore) as of July 19. On Wednesday, July 19, the share price of his company was Rs 1,085.50.
Shanghvi also holds the position of chairman at Sun Pharma Advanced Research Company Ltd and the Shantilal Shanghvi Foundation. In 2016, the Government of India honored him with the Padma Shri award. Dilip Shanghvi comes from a Jain family and was born in the small town of Amreli in Gujarat. He is the son of Shantilal Shanghvi and Kumud Shanghvi. He pursued a B.Com degree from the University of Calcutta.
He is an alumnus of JJ Ajmera High School and Bhawanipur Education Society College, where he completed his schooling and graduation, respectively. Earlier, he used to assist his father in his wholesale dealership of medicines, primarily generic drugs, in Kolkata.
During this time, he conceived the idea of manufacturing his own drugs rather than selling products made by others. In 1983, when he was 27 years old, Shanghvi inaugurated his first manufacturing unit with an initial capital of nearly Rs 10,000. He named his venture Sun Pharmaceutical Industries.